Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women
Nature medicine, 2018.
Several clinical trials have demonstrated that antiretroviral (ARV) drugs taken as pre-exposure prophylaxis (PrEP) can prevent HIV infection, with the magnitude of protection ranging from -49 to 86% (refs. ). Although these divergent outcomes are thought to be due primarily to differences in product adherence, biological factors likely co...More
Full Text (Upload PDF)